The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
CAR-T cell manufacturing: Major process parameters and next-generation strategies
Open accessAbstract
Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430 · cited 1×
“…ratios may confer superior antitumor efficacy (Sommermeyer et al., 2016), although clear distinctions in efficacy and safety profiles between liso-cel and other products will require broader and longer-term data collection (Abramson et al., 2020, 2023; Locke et al., 2022; Schuster et al., 2021).”
BackgroundCRISPR–Cas9 Structures and Mechanisms
Jiang, F., & Doudna, J. A. (2017) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010822 · Cited by 2,029
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 2×
“This strategy commandeers the endogenous gene regulatory mechanisms that dynamically control TCR expression levels in response to T-cell activation states, with data suggesting that the resulting CAR-T cells may be more efficacious than virally integrated CAR-T cells (Eyquem et al., 2017).”
BackgroundLong, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116133 · Cited by 1,607
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,227
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen, A., Müller, F., Mougiakakos, D., Böltz, S., Wilhelm, A., Aigner, M., Völkl, S., Simon, D., Kleyer, A., Munoz, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02017-5 · Cited by 1,092
CAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · HAL · Cited by 926
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
Melenhorst, J. J., Chen, G. M., Wang, M., Porter, D. L., Chen, C., Collins, M. A., Gao, P., Bandyopadhyay, S., Sun, H., Zhao, Z., et al. (2022) · Nature · doi:10.1038/s41586-021-04390-6 · Cited by 923
Human memory T cells: generation, compartmentalization and homeostasis
Farber, D. L., Yudanin, N. A., & Restifo, N. P. (2014) · Nature Reviews Immunology · doi:10.1038/nri3567 · Cited by 897 · cited 1×
“…greater potential for long-term persistence and produce lower levels of inflammatory cytokines, which could together enable durable anti-tumor response while avoiding severe acute toxicities such as cytokine release syndrome (CRS; Chang et al., 2014; Farber et al., 2014; Kishton et al., 2017).”
BackgroundSommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862 · cited 1×
“…cell therapy appeared to correlate with the expansion of a single CAR-T cell clone whose CAR transgene was randomly inserted in the TET2 locus, thereby knocking out the only functional TET2 copy as the patient had a congenital mis-sense mutation in the other TET2 allele (Fraietta et al., 2018b).”
BackgroundCilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827
Berger, C., Jensen, M. C., Lansdorp, P. M., Gough, M., Elliott, C., & Riddell, S. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32103 · Cited by 824
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., et al. (2022) · Nature · doi:10.1038/s41586-022-04489-4 · Cited by 823
Kamdar, M., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00662-6 · Cited by 799
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S., & Stephan, M. T. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.57 · Cited by 785
Global Manufacturing of CAR T Cell Therapy
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.006 · Cited by 765
Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00591-x · Cited by 666
Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0201-9 · Cited by 659
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., Good, Z., Belk, J. A., Daniel, B., Klysz, D., et al. (2021) · Science · doi:10.1126/science.aba1786 · Cited by 607
Signals required for programming effector and memory development by CD8+ T cells
Mescher, M. F., Curtsinger, J. M., Agarwal, P., Casey, K. A., Gerner, M., Hammerbeck, C. D., Popescu, F., & Xiao, Z. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00382.x · Cited by 601
Deng, Q., Han, G., Puebla-Osorio, N., Ma, M. C. J., Strati, P., Chasen, B., Dai, E., Dang, M., Jain, N., Yang, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1061-7 · Cited by 600
Schuster, S. J., Tam, C. S., Borchmann, P., Worel, N., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S., Bishop, M. R., Damon, L. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00375-2 · Cited by 584
Molecular regulation of effector and memory T cell differentiation
Chang, J. T., Wherry, E. J., & Goldrath, A. W. (2014) · Nature Immunology · doi:10.1038/ni.3031 · Cited by 582
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
Golubovskaya, V., & Wu, L. (2016) · Cancers · doi:10.3390/cancers8030036 · Cited by 577
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Fowler, N. H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L., Chavez, J. C., Bachy, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01622-0 · Cited by 555
Navigating CAR-T cells through the solid-tumour microenvironment
Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 551
Self-citationMetabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.016 · Cited by 548
Themeli, M., Kloss, C. C., Ciriello, G., Fedorov, V. D., Perna, F., Gonen, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2678 · Cited by 473
Shah, N. N., Johnson, B. D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C. A., Krueger, W., Worden, A. A., Kadan, M. J., Yim, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1081-3 · Cited by 468 · cited 1×
“…confirmed that patients treated with fresh CAR-T cell products experienced substantially higher complete response rates (80% fresh versus 29% cryopreserved) as well as greater CAR-T cell expansion and persistence compared with patients treated with cryopreserved CAR-T cells (Shah et al., 2020).”
ResultZhao, Y., Moon, E., Carpenito, C., Paulos, C. M., Liu, X., Brennan, A. L., Chew, A., Carroll, R. G., Scholler, J., Levine, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2880 · Cited by 450
Bos, R., & Sherman, L. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1322 · Cited by 443
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
Abramson, J. S., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., et al. (2023) · Blood · doi:10.1182/blood.2022018730 · Cited by 399
COOPERATION BETWEEN CD4+AND CD8+T CELLS: When, Where, and How
Castellino, F., & Germain, R. N. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115825 · Cited by 376
Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells
Cheung, A. S., Zhang, D. K. Y., Koshy, S. T., & Mooney, D. J. (2018) · Nature Biotechnology · doi:10.1038/nbt.4047 · Cited by 372
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Dimitri, A., Herbst, F., & Fraietta, J. A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01559-z · Cited by 352
CD19 CAR T cell product and disease attributes predict leukemia remission durability
Finney, O. C., Brakke, H., Rawlings-Rhea, S., Hicks, R., Doolittle, D., Lopez, M., Futrell, B., Orentas, R. J., Li, D., Gardner, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125423 · Cited by 346
Wang, X., Popplewell, L. L., Wagner, J. R., Naranjo, A., Blanchard, M. S., Mott, M. R., Norris, A. P., Wong, C. W., Urak, R. Z., Chang, W.-C., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686725 · Cited by 322
Rapid manufacturing of non-activated potent CAR T cells
Ghassemi, S., Durgin, J. S., Nunez-Cruz, S., Patel, J., Leferovich, J., Pinzone, M., Shen, F., Cummins, K. D., Plesa, G., Cantu, V. A., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00842-6 · Cited by 302
Hansen, D. K., Sidana, S., Peres, L. C., Colin Leitzinger, C., Shune, L., Shrewsbury, A., Gonzalez, R., Sborov, D. W., Wagner, C., Dima, D., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01365 · Cited by 293
Non-viral precision T cell receptor replacement for personalized cell therapy
Foy, S. P., Jacoby, K., Bota, D. A., Hunter, T., Pan, Z., Stawiski, E., Ma, Y., Lu, W., Peng, S., Wang, C. L., et al. (2023) · Nature · doi:10.1038/s41586-022-05531-1 · Cited by 285
High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation
Zhao, Y., Zheng, Z., Cohen, C. J., Gattinoni, L., Palmer, D. C., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.688 · Cited by 283
Seet, C. S., He, C., Bethune, M. T., Li, S., Chick, B., Gschweng, E. H., Zhu, Y., Kim, K., Kohn, D. B., Baltimore, D., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4237 · Cited by 276
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma
Tong, C., Zhang, Y., Liu, Y., Ji, X., Zhang, W.-Y., Guo, Y., Han, X., Ti, D., Dai, H., Wang, C., et al. (2020) · Blood · doi:10.1182/blood.2020005278 · Cited by 275
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Haradhvala, N. J., Leick, M. B., Maurer, K., Gohil, S. H., Larson, R. C., Yao, N., Gallagher, K. M. E., Katsis, K., Frigault, M. J., Southard, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01959-0 · Cited by 271
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Wang, Z., Li, N., Feng, K., Chen, M., Zhang, Y., Liu, Y., Yang, Q., Nie, J., Tang, N., Zhang, X., et al. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00749-x · Cited by 265
Vigdal, T. J., Kaufman, C. D., Izsvák, Z., Voytas, D. F., & Ivics, Z. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00991-9 · Cited by 258
Monjezi, R., Miskey, C., Gogishvili, T., Schleef, M., Schmeer, M., Einsele, H., Ivics, Z., & Hudecek, M. (2017) · Leukemia · doi:10.1038/leu.2016.180 · Cited by 258
Arcangeli, S., Bove, C., Mezzanotte, C., Camisa, B., Falcone, L., Manfredi, F., Bezzecchi, E., El Khoury, R., Norata, R., Sanvito, F., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150807 · Cited by 251
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Ehlinger, Z. J., Kurra, S., Desai, M. H., Reynolds, W. D., Wong Lin, A., Vandris, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01960-7 · Cited by 248
Sehgal, A., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G. C., Godwin, J. E., Reagan, P. M., Wagner-Johnston, N., Essell, J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00339-4 · Cited by 242
Mock, U., Nickolay, L., Philip, B., Cheung, G. W.-K., Zhan, H., Johnston, I. C. D., Kaiser, A. D., Peggs, K., Pule, M., Thrasher, A. J., et al. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.009 · Cited by 237
Micklethwaite, K. P., Gowrishankar, K., Gloss, B. S., Li, Z., Street, J. A., Moezzi, L., Mach, M. A., Sutrave, G., Clancy, L. E., Bishop, D. C., et al. (2021) · Blood · doi:10.1182/blood.2021010858 · Cited by 226 · cited 1×
“Post-hoc analysis indicated that the malignant CAR-T cells did not contain transgene insertion into known oncogenic sites but displayed significant copy-number gains and losses of multiple chromosomes as well as transcriptional readthrough from the transgene promoter (Micklethwaite et al., 2021).”
BackgroundZah, E., Nam, E., Bhuvan, V., Tran, U., Ji, B. Y., Gosliner, S. B., Wang, X., Brown, C. E., & Chen, Y. Y. (2020) · Nature Communications · doi:10.1038/s41467-020-16160-5 · Cited by 222
Self-citationSchultz, L. M., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J.-A., Moskop, A., Margossian, S. P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.20.03585 · Cited by 220
Pfeiffer, A., Thalheimer, F. B., Hartmann, S., Frank, A. M., Bender, R. R., Danisch, S., Costa, C., Wels, W. S., Modlich, U., Stripecke, R., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809158 · Cited by 212
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
Tsuchida, C. A., Brandes, N., Bueno, R., Trinidad, M., Mazumder, T., Yu, B., Hwang, B., Chang, C., Liu, J., Sun, Y., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.041 · Cited by 209
Chen, G. M., Chen, C., Das, R. K., Gao, P., Chen, C.-H., Bandyopadhyay, S., Ding, Y.-Y., Uzun, Y., Yu, W., Zhu, Q., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1677 · Cited by 207
In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes
Agarwal, S., Hanauer, J. D. S., Frank, A. M., Riechert, V., Thalheimer, F. B., & Buchholz, C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.005 · Cited by 191
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Puig-Saus, C., Sennino, B., Peng, S., Wang, C. L., Pan, Z., Yuen, B., Purandare, B., An, D., Quach, B. B., Nguyen, D., et al. (2023) · Nature · doi:10.1038/s41586-023-05787-1 · Cited by 190
Self-citationPrommersberger, S., Reiser, M., Beckmann, J., Danhof, S., Amberger, M., Quade-Lyssy, P., Einsele, H., Hudecek, M., Bonig, H., & Ivics, Z. (2021) · Gene Therapy · doi:10.1038/s41434-021-00254-w · Cited by 182
Bishop, D. C., Clancy, L. E., Simms, R., Burgess, J., Mathew, G., Moezzi, L., Street, J. A., Sutrave, G., Atkins, E., McGuire, H. M., et al. (2021) · Blood · doi:10.1182/blood.2021010813 · Cited by 177 · cited 1×
“In a phase 1 clinical trial, two patients treated with allogeneic CD19 CAR-T cell products generated with the piggyBac transposon system developed CAR-T cell – derived lymphoma, resulting in one fatality (Bishop et al., 2021).”
BackgroundRoddie, C., Neill, L., Osborne, W., Iyengar, S., Tholouli, E., Irvine, D. A., Chaganti, S., Besley, C., Bloor, A. J. C., Jones, C. H., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009019 · Cited by 176
Labbé, R. P., Vessillier, S., & Rafiq, Q. A. (2021) · Viruses · doi:10.3390/v13081528 · Cited by 175
Zhang, Y., Zhang, Z., Ding, Y., Fang, Y., Wang, P., Chu, W., Jin, Z., Yang, X., Wang, J., Lou, J., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03613-7 · Cited by 169
TET2 guards against unchecked BATF3-induced CAR T cell expansion
Jain, N., Zhao, Z., Feucht, J., Koche, R. P., Iyer, A., Dobrin, A., Mansilla‐Soto, J., Yang, J. L., Zhan, Y. A., Lopez, M. A., et al. (2023) · Nature · doi:10.1038/s41586-022-05692-z · Cited by 168
Bai, Z., Woodhouse, S., Zhao, Z., Arya, R., Govek, K., Kim, D., Lundh, S., Baysoy, A., Sun, H., Deng, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj2820 · Cited by 166
Shah, N. N., Qin, H., Yates, B., Su, L., Shalabi, H., Raffeld, M., Ahlman, M. A., Stetler-Stevenson, M., Yuan, C., Guo, S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000219 · Cited by 165
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Hamieh, M., Mansilla-Soto, J., Rivière, I., & Sadelain, M. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0101 · Cited by 163
Optimizing CAR-T cell manufacturing processes during pivotal clinical trials
Tyagarajan, S., Spencer, T., & Smith, J. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.018 · Cited by 161
Gogol-Döring, A., Ammar, I., Gupta, S., Bunse, M., Miskey, C., Chen, W., Uckert, W., Schulz, T. F., Izsvák, Z., & Ivics, Z. (2016) · Molecular Therapy · doi:10.1038/mt.2016.11 · Cited by 160
Sandoval-Villegas, N., Nurieva, W., Amberger, M., & Ivics, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105084 · Cited by 159
Cornetta, K. G., & Anderson, W. F. (1989) · Journal of Virological Methods · doi:10.1016/0166-0934(89)90132-8 · Cited by 152
Stroncek, D. F., Ren, J., Lee, D. W., Tran, M., Frodigh, S. E., Sabatino, M., Khuu, H., Merchant, M. S., & Mackall, C. L. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.04.003 · Cited by 148
Dickinson, M. J., Barba, P., Jaeger, U., Shah, N. N., Blaise, D., Briones, J., Shune, L. O., Boissel, N., Bondanza, A., Mariconti, L., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1276 · Cited by 147
Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input
Wang, V., Gauthier, M., Decot, V., Reppel, L., & Bensoussan, D. (2023) · Cancers · doi:10.3390/cancers15041003 · Cited by 143
Michels, K. R., Sheih, A., Hernández, S., Brandes, A., Parrilla, D., Irwin, B., Perez, A. M., Ting, H.-A., Nicolai, C. J., Gervascio, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006292 · Cited by 140
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
Roberts, Z. J., Better, M., Bot, A. I., Roberts, M. R., & Ribas, A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1387905 · Cited by 139
Marcucci, K. T., Jadlowsky, J. K., Hwang, W., Suhoski, M. M., Gonzalez, V. E., Kulikovskaya, I. M., Gupta, M., Lacey, S. F., Plesa, G., Chew, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.012 · Cited by 138
Yang, J., He, J., Zhang, X., Li, J., Wang, Z., Zhang, Y., Qiu, L., Wu, Q., Sun, Z., Ye, X., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00694-6 · Cited by 135
Arcangeli, S., Falcone, L., Camisa, B., De Girardi, F., Biondi, M., Giglio, F., Ciceri, F., Bonini, C., Bondanza, A., & Casucci, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01217 · Cited by 134
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
Michels, A., Ho, N., & Buchholz, C. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.018 · Cited by 134
Zhu, F., Shah, N., Xu, H., Schneider, D., Orentas, R., Dropulic, B., Hari, P., & Keever-Taylor, C. A. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2017.09.005 · Cited by 120
Larson, S. M., Walthers, C. M., Ji, B., Ghafouri, S. N., Naparstek, J., Trent, J., Chen, J. M., Roshandell, M., Harris, C. M., Khericha, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0964 · Cited by 116
Self-citationYoon, S. H., Lee, J. M., Cho, H. I., Kim, E. K., Kim, H. S., Park, M. Y., & Kim, T. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.98 · Cited by 104
Ueda, T., Shiina, S., Iriguchi, S., Terakura, S., Kawai, Y., Kabai, R., Sakamoto, S., Watanabe, A., Ohara, K., Wang, B., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00969-0 · Cited by 103
EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity
Jing, R., Scarfò, I., Najia, M. A. T., da Rocha, E. L., Han, A., Sanborn, M., Bingham, T., Kubaczka, C., Jha, D. K., Falchetti, M., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.06.014 · Cited by 100
Enhancing CAR-T cell functionality in a patient-specific manner
Zhang, D. K. Y., Adu‐Berchie, K., Iyer, S., Liu, Y., Cieri, N., Brockman, J. M., Neuberg, D. S., Wu, C. J., & Mooney, D. J. (2023) · Nature Communications · doi:10.1038/s41467-023-36126-7 · Cited by 99
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products
Cornetta, K., Duffy, L., Turtle, C. J., Jensen, M., Forman, S., Binder-Scholl, G., Fry, T., Chew, A., Maloney, D. G., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.008 · Cited by 98
CD4 + T cells support cytotoxic T lymphocyte priming by controlling lymph node input
Kumamoto, Y., Mattei, L. M., Sellers, S., Payne, G. W., & Iwasaki, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100567108 · Cited by 95
Jagannath, S., Lin, Y., Goldschmidt, H., Reece, D., Nooka, A., Senin, A., Rodriguez-Otero, P., Powles, R., Matsue, K., Shah, N., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00507-2 · Cited by 90
Expanding access to CAR T cell therapies through local manufacturing
Elsallab, M., & Maus, M. V. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01981-8 · Cited by 90
van der Stegen, S. J. C., Lindenbergh, P. L., Petrovic, R. M., Xie, H., Diop, M. P., Alexeeva, V., Shi, Y., Mansilla‐Soto, J., Hamieh, M., Eyquem, J., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00915-0 · Cited by 84
Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
Huckaby, J. T., Landoni, E., Jacobs, T. M., Savoldo, B., Dotti, G., & Lai, S. K. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002737 · Cited by 83
Non-viral chimeric antigen receptor (CAR) T cells going viral
Balke‐Want, H., Keerthi, V., Cadiñanos-Garai, A., Fowler, C., Gkitsas-Long, N., Brown, A. K., Tunuguntla, R. H., Abou‐El‐Enein, M., & Feldman, S. A. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100375 · Cited by 81
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
Mian, A., & Hill, B. T. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1889510 · Cited by 78
Frank, A. M., Braun, A. H., Scheib, L., Agarwal, S., Schneider, I. C., Fusil, F., Perian, S., Sahin, U., Thalheimer, F. B., Verhoeyen, E., et al. (2020) · PubMed · doi:10.1182/bloodadvances.2020002229 · Cited by 77
Casati, A., Varghaei-Nahvi, A., Feldman, S. A., Assenmacher, M., Rosenberg, S. A., Dudley, M. E., & Scheffold, A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1459-x · Cited by 73
Aleksandrova, K., Leise, J., Priesner, C., Melk, A., Kubaink, F., Abken, H., Hombach, A. A., Aktas, M., Essl, M., Bürger, I., et al. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000495772 · Cited by 67
Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan
Jo, T., Yoshihara, S., Okuyama, Y., Fujii, K., Henzan, T., Kahata, K., Yamazaki, R., Takeda, W., Umezawa, Y., Fukushima, K., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18831 · Cited by 64
Shao, L., Shi, R., Zhao, Y., Liu, H., Lu, A., Ma, J., Cai, Y., Fuksenko, T., Pelayo, A., Shah, N. N., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03729-5 · Cited by 59
Kourelis, T., Bansal, R., Berdeja, J. G., Siegel, D. S. D., Patel, K. K., Mailankody, S., Htut, M., Shah, N. D., Wong, S. W. K., Sidana, S., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.01.012 · Cited by 57
Delville, M., Soheili, T. S., Bellier, F., Durand, A., Denis, A., Lagresle‐Peyrou, C., Cavazzana, M., André‐Schmutz, I., & Six, E. M. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.08.002 · Cited by 52
Wang, X., Bórquez-Ojeda, O., Stefanski, J., Du, F., Qu, J., Chaudhari, J., Thummar, K., Zhu, M., Shen, L., Hall, M. J., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.014 · Cited by 51
Role of bridging therapy during chimeric antigen receptor T cell therapy
Bhaskar, S., Dholaria, B., Sengsayadeth, S. M., Savani, B. N., & Oluwole, O. O. (2021) · eJHaem · doi:10.1002/jha2.335 · Cited by 48
Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism
Gao, T. A., & Chen, Y. Y. (2022) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-092120-092914 · Cited by 44
Self-citationAutomated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform
Trainor, N., Purpura, K. A., Middleton, K., Fargo, K., Hails, L., Vicentini-Hogan, M., McRobie, C., Daniels, R., Densham, P., Gardin, P., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.07.012 · Cited by 44
Shahid, S., Ramaswamy, K., Flynn, J. R., Mauguen, A., Perica, K., Park, J. H., Forlenza, C. J., Shukla, N. N., Steinherz, P. G., Margossian, S. P., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.11.014 · Cited by 43
CAR T cell viability release testing and clinical outcomes: is there a lower limit?
Chong, E. A., Levine, B. L., Grupp, S. A., Suhoski, M. M., Siegel, D. L., Maude, S. L., Gladney, W. L., Frey, N. V., Porter, D. L., Hwang, W., et al. (2019) · Blood · doi:10.1182/blood.2019002258 · Cited by 42
Chen, A. J., Zhang, J., Agarwal, A., & Lakdawalla, D. N. (2022) · Value in Health · doi:10.1016/j.jval.2022.02.007 · Cited by 38
Sperling, A. S., Derman, B. A., Nikiforow, S., Im, S.-Y., Ikegawa, S., PRABHALA, R. H., Rodriguez, D. H., Li, Y., Quinn, D. S., Pearson, D. E., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.16_suppl.8004 · Cited by 38
Novel extragenic genomic safe harbors for precise therapeutic T cell engineering
Odak, A., Yuan, H., Feucht, J., Cantu, A., Mansilla‐Soto, J., Kogel, F., Eyquem, J., Everett, J. K., Bushman, F. D., Leslie, C. S., et al. (2023) · Blood · doi:10.1182/blood.2022018924 · Cited by 36
Flinn, I. W., Jaeger, U., Shah, N. N., Blaise, D., Briones, J., Shune, L. O., Boissel, N., Bondanza, A., Lu, D., Zhu, X., et al. (2021) · Blood · doi:10.1182/blood-2021-146268 · Cited by 35
Künkele, A., Brown, C., Beebe, A., Mgebroff, S., Johnson, A., Taraseviciute, A., Rolczynski, L. S., Chang, C. A., Finney, O. C., Park, J. R., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.10.004 · Cited by 34
Rajabzadeh, A., Hamidieh, A. A., & Rahbarizadeh, F. (2021) · BMC Molecular and Cell Biology · doi:10.1186/s12860-021-00397-z · Cited by 33
Ceppi, F., Wilson, A. L., Annesley, C., Kimmerly, G. R., Summers, C. N., Brand, A., Seidel, K. D., Wu, Q. V., Beebe, A., Brown, C., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0501 · Cited by 29
Teoh, J. J., & Brown, L. F. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.03.013 · Cited by 29
Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy
Schambach, A., Morgan, M. A., & Fehse, B. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.013 · Cited by 28
Doms, R. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800964-2.00003-3 · Cited by 26
Hadidi, S. A., Szabó, A., Esselmann, J., Hammons, L. R., Hussain, M., Ogunsesan, Y., Thalambedu, N., Khan, F., Sethi, J., Janardan, A., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01905-1 · Cited by 26
Mateos, M., Weisel, K. C., Martin, T. G., Berdeja, J. G., Jakubowiak, A. J., Stewart, A. K., Jagannath, S., Lin, Y., Diels, J., Ghilotti, F., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280482 · Cited by 24
Lee, D. H., Cervantes-Contreras, F., Lee, S. Y., Green, D. J., & Till, B. G. (2018) · Blood · doi:10.1182/blood-2018-99-111576 · Cited by 22
Martin, Y. S., Franz, J. K., Agha, M., & Lazarus, H. M. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101095 · Cited by 21
Lyon, D., Lapteva, N., & Gee, A. P. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.003 · Cited by 14
Release Assays and Potency Assays for CAR T-Cell Interventions
Dias, J., Cadiñanos-Garai, A., & Roddie, C. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-30040-0_8 · Cited by 11
Manufacturing of CAR-T Cells: The Assembly Line
Wang, X., & Rivière, I. (2022) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_8 · Cited by 2
Cited by
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Du, B., Qin, J., Lin, B., Zhang, J., Li, D., & Liu, M. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.019 · Cited by 254
Cost-effective strategies for CAR-T cell therapy manufacturing
Abdo, L., Batista-Silva, L. R., & Bonamino, M. H. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.200980 · Cited by 54
Marton, C., Clémenceau, B., Dachy, G., Demerle, C., Derenne, S., Ferrand, C., Giverne, C., Latouche, J.-B., Lemée, L., Martinet, J., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02637-8 · Cited by 16
Egan, J. R., Marí‐Buyé, N., Benítez‐Cano, E. V., Costa, M., Wanika, L., Chappell, M. J., Schultz, U., Ochs, J., Effenberger, M., Horna, D., et al. (2025) · Biotechnology Progress · doi:10.1002/btpr.70045 · Cited by 10
Metadata
- Authors
- Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2024-01-16
- Volume
- 221
- Issue
- 2
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W4390909128
- Cited by
- 303
- References
- 143
- FWCI
- 31.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.